2022
Toward Precision Phenotyping of Multiple Sclerosis
Pitt D, Lo CH, Gauthier SA, Hickman RA, Longbrake E, Airas LM, Mao-Draayer Y, Riley C, De Jager PL, Wesley S, Boster A, Topalli I, Bagnato F, Mansoor M, Stuve O, Kister I, Pelletier D, Stathopoulos P, Dutta R, Lincoln MR. Toward Precision Phenotyping of Multiple Sclerosis. Neurology Neuroimmunology & Neuroinflammation 2022, 9: e200025. PMID: 36041861, PMCID: PMC9427000, DOI: 10.1212/nxi.0000000000200025.Peer-Reviewed Original ResearchConceptsMultiple sclerosisSecondary progressive multiple sclerosisPathological processesProgressive multiple sclerosisKey pathological processClinical trial designDevelopment of biomarkersPerilesional inflammationNeuroaxonal degenerationMS phenotypeTrial designClinical importancePersonalized careM phenotypeSclerosisPhenotypeRemyelinationInflammationSyndromePrognosticationDegenerationProgressionBiomarkersCare
1999
Neuregulin and erbB receptor expression in normal and diseased human white matter
Cannella B, Pitt D, Marchionni M, Raine C. Neuregulin and erbB receptor expression in normal and diseased human white matter. Journal Of Neuroimmunology 1999, 100: 233-242. PMID: 10695733, DOI: 10.1016/s0165-5728(99)00201-5.Peer-Reviewed Original ResearchConceptsGlial growth factor 2Multiple sclerosisErbB receptor expressionWhite matterHuman white matterReceptor expressionCases of MSHuman lymph node tissueAreas of remyelinationLymph node tissueGrowth factor 2Autoimmune demyelinationMicroglial cellsNeurologic diseaseMS lesionsNode tissueMitogenic effectWestern blotWestern blottingOligodendrocytesReceptorsRemyelinationWidespread expressionFactor 2Lymphocytes